



Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2007

November 1, 2006

Podcast to be Available Following Conference Call

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 1, 2006--Alkermes, Inc. (Nasdaq: ALKS) will host a conference call at 4:15 p.m. EST on Thursday, November 2, 2006 to discuss the Company's financial results for its second quarter of fiscal 2007. Management will review the quarter and provide an update on the Company.

The conference call will be webcast on the investor relations section of Alkermes' website at www.alkermes.com or may be accessed by dialing 1-866-244-4526 for domestic callers and 1-703-639-1172 for international callers. The conference call ID number is 983200.

A replay of the conference call will be available from 7:15 p.m. EST on Thursday, November 2, 2006 through 5:00 p.m. EST on Tuesday, November 7, 2006, and may be accessed by visiting Alkermes' website or by dialing 1-888-266-2081 for domestic callers and 1-703-925-2533 for international callers. The replay access code is 983200. Alkermes is also providing a podcast MP3 file available for download on the Alkermes website, which will be available shortly following the conference call and will be available until Thursday, November 9, 2006.

Alkermes, Inc. is a biotechnology company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company has two commercial products. RISPERDAL(R) CONSTA(R) ((risperidone) long-acting injection), the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, is marketed worldwide by Janssen-Cilag (Janssen), a wholly owned division of Johnson & Johnson. VIVITROL(R) (naltrexone for extended-release injectable suspension) is the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and is marketed in the United States primarily by Cephalon, Inc. The Company has a pipeline of extended-release injectable products and pulmonary products based on its proprietary technology and expertise. Alkermes' product development strategy is twofold: the Company partners its proprietary technology systems and drug delivery expertise with several of the world's finest pharmaceutical companies; and it also develops novel, proprietary drug candidates for its own account. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

VIVITROL(R) is a trademark of Cephalon, Inc. and RISPERDAL(R) CONSTA(R) is a registered trademark of Johnson & Johnson Corporation.

CONTACT: Debra Koufos Associate, Corporate Communications Alkermes, Inc. (617) 583-6220 SOURCE: Alkermes, Inc.